PMID- 34540027
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210921
IS  - 1943-8141 (Print)
IS  - 1943-8141 (Electronic)
IS  - 1943-8141 (Linking)
VI  - 13
IP  - 8
DP  - 2021
TI  - Therapeutic effects of alteplase intravenous thrombolysis on different types of 
      acute cerebral infarction: a controlled randomized analysis.
PG  - 9129-9135
AB  - OBJECTIVE: To test the effects of alteplase (PA) intravenous thrombolysis on 
      different types of acute cerebral infarction (ACI). METHODS: One hundred and ten 
      patients with the ACI admitted from April 2018 to April 2019 were selected and 
      randomly assigned to a research group and a reference group equally. The two 
      groups received conventional treatment with a subcutaneous injection of low 
      molecular weight heparin calcium of 5000 IU, and the research group received 
      additional PA intravenous thrombolysis treatment. The therapeutic effects of the 
      two groups were compared. RESULTS: There were no significant differences in terms 
      of general information and National Institutes of Health Stroke Scale (NIHSS) 
      score at T0 (P>0.05) between the two groups; the research group garnered better 
      results in the NIHSS scores at T1, T2, T3, and T4 than the reference group 
      (P<0.001); a decrease was found in the Modified Rankin Scale (MRS) after 
      treatment (P<0.001), with lower scores in the research group (P<0.001); the 
      research group obtained a higher total effective rate than the reference group 
      (P<0.05). Remarkably higher Barthel scores of the two groups after treatment were 
      found (P<0.001), with higher scores collected from the research group (P<0.001); 
      patients in the research group enjoyed a lower incidence of bleeding events than 
      the reference group (P<0.05). The levels of Interleukin-1beta (IL-1beta), 
      high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor alpha 
      (TNF-alpha), superoxide dismutase (SOD), glutathione peroxidase (GSH-px), and 
      malondialdehyde (MDA) were apparently optimized after treatment, with superior 
      results observed in the research group (P<0.05). CONCLUSION: PA intravenous 
      thrombolysis effectively improves the neurological function of patients with 
      different types of ACI and their quality of life, and reduces bleeding events, 
      which is worthy of promotion.
CI  - AJTR Copyright (c) 2021.
FAU - Wang, Anning
AU  - Wang A
AD  - Department of Neurology, Weifang People's Hospital Weifang, China.
FAU - Zhang, Yumei
AU  - Zhang Y
AD  - Department of Family Planning Clinic, Weifang People's Hospital Weifang, China.
LA  - eng
PT  - Journal Article
DEP - 20210815
PL  - United States
TA  - Am J Transl Res
JT  - American journal of translational research
JID - 101493030
PMC - PMC8430132
OTO - NOTNLM
OT  - PA intravenous thrombolysis
OT  - different types of ACI
OT  - therapeutic effects
COIS- None.
EDAT- 2021/09/21 06:00
MHDA- 2021/09/21 06:01
PMCR- 2021/08/15
CRDT- 2021/09/20 06:06
PHST- 2021/04/01 00:00 [received]
PHST- 2021/05/17 00:00 [accepted]
PHST- 2021/09/20 06:06 [entrez]
PHST- 2021/09/21 06:00 [pubmed]
PHST- 2021/09/21 06:01 [medline]
PHST- 2021/08/15 00:00 [pmc-release]
PST - epublish
SO  - Am J Transl Res. 2021 Aug 15;13(8):9129-9135. eCollection 2021.